 CAMBRIDGE, Mass., Sept. 07, 2022 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the following upcoming investor conferences in September: 